Tom McKillop
Tom McKillop
Sir Thomas Fulton Wilson "Tom" McKillop, FRSis a Scottish chemist, who was CEO of AstraZeneca PLC from 1999 until 2006 and chairman of the RBS Group from 2006 until 2008...
bigger engage major none reason strategic
We have no strategic need to be bigger -- none at all. So there is no reason to engage in major M&A activity.
devices history partly period realistic review reviews tend
The history of this division, partly because of the devices element, is that reviews and approvals tend to be very slow, so we made realistic to conservative assumptions on what the review period should be.
approval period review time typical
The typical review time in this division, the period to approval, is something like two years,
argue breach chance discovered fight free generic good patents strongly unless
We will fight in the courts, ... We will argue very strongly that unless a generic manufacturer has discovered its own way that is free of our patents of formulating the product, that they're in breach of our patents. We think we have a good chance of winning.